Menu
Logo

DARZALEX® SC development

DARZALEX® SC was developed to reduce patient and provider burden without compromising safety and efficacy

It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Manage cookie settings

Adapted with permission. © Halozyme, Inc. 2018. All rights reserved. © Janssen Pharmaceuticals, Inc.

Related content

DARZALEX® SC home

DARZALEX® SC handling and administration
Handling and administration demonstration & information

DARZALEX® SC studies
Overview of the DARZALEX® SC PAVO, COLUMBA and PLEIADES studies

DARZALEX® SC support materials
A range of materials, including a practical guide, in-clinic poster and patient materials

DARZALEX® SC MOA

DARZALEX® SC contains recombinant human hyaluronidase PH20 (rHuPH20; ENHANZE® drug delivery technology), an enzyme that disrupts the extracellular matrix to open the subcutaneous space, allowing access to the lymphatic and capillary vessels. The mechanism permits DARZALEX® SC to be absorbed quickly into the systemic circulation.[1][2][3]

DARZALEX® SC dose selection

The DARZALEX® SC 1,800 mg flat dose was selected based on the phase 1b PAVO study[4][5]

similar-clinical-response-rates
acceptable-pharmacokinetic-profile
comparable-safety-profile

DARZALEX® SC provides:[1]

shorter-administration
ready-to-use-vial
no-need-for-iv-access
greater-satisfaction

* Compared with DARZALEX® IV.

Quick downloads

SC Checklist beginning of treatment

Includes a first use checklist of Darzalex® SC.

Darzalex® SC Practical Guide

Includes DARZALEX® SC handling and administration info, pre and post-injection medications, and more

Glossary

IRR: infusion-related reaction

IV: intravenous

MOA: mode of action

rHuPH20: recombinant human hyaluronidase PH20

SC: subcutaneous

Para visualizar o IECRCM de Darzalex, veja aqui.
CP-287862 - março 2022